[Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment

<div>Pathway enrichment analyses of the common DEGs of CLL patients. (a) Patient 1, (b) patient 2, and (c) patient 3.</div>

Computational and Mathematical Methods in Medicine

fig4

Figure 4

Figure 4: [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 

Figure 4 | [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 